What is HC Wainwright's Estimate for SMMT FY2026 Earnings?

Key Points

• HC Wainwright raised its FY2026 EPS estimate for Summit Therapeutics to a loss of $1.04 per share from a loss of $1.06, and maintained its Buy rating. Its FY2027 forecast is a loss of $0.98 per share.
• Analyst sentiment is broadly favorable: MarketBeat reports a “Moderate Buy” consensus rating and an average price target of $28.61; the stock opened at $16.33.

Summit Therapeutics PLC (NASDAQ:SMMT - Free Report) - Equities researchers at HC Wainwright lifted their FY2026 earnings per share estimates for shares of Summit Therapeutics in a report issued on Thursday, November 5th. HC Wainwright analyst M. Kapoor now expects that the company will earn ($1.04) per share for the year, up from their prior estimate of ($1.06). HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Summit Therapeutics' current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Summit Therapeutics' Q4 2026 earnings at ($0.26) EPS, Q1 2027 earnings at ($0.24) EPS, Q2 2027 earnings at ($0.24) EPS, Q3 2027 earnings at ($0.25) EPS, Q4 2027 earnings at ($0.25) EPS and FY2027 earnings at ($0.98) EPS.

Several other research firms have also issued reports on SMMT. Citigroup reissued a "market outperform" rating on shares of Summit Therapeutics in a research note on Tuesday, October 27th. Leerink Partners upgraded Summit Therapeutics from an "underperform" rating to a "market perform" rating and upped their target price for the stock from $12.00 to $13.00 in a research note on Wednesday, August 12th. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Summit Therapeutics in a report on Monday, October 5th. Barclays lifted their price target on Summit Therapeutics from $18.00 to $20.00 and gave the company an "equal weight" rating in a research report on Thursday, October 1st. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Summit Therapeutics in a report on Tuesday, September 22nd. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Summit Therapeutics has an average rating of "Moderate Buy" and an average price target of $28.61.

Summit Therapeutics Price Performance

SMMT opened at $16.33 on Monday. The firm has a market capitalization of $13.06 billion, a P/E ratio of -15.26 and a beta of -1.49. Summit Therapeutics has a one year low of $12.07 and a one year high of $29.23. The company has a fifty day moving average price of $16.25 and a 200-day moving average price of $16.15.

Institutional Trading of Summit Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. IFP Advisors Inc grew its position in Summit Therapeutics by 792.3% during the third quarter. IFP Advisors Inc now owns 1,508 shares of the company's stock valued at $26,000 after acquiring an additional 1,339 shares during the last quarter. Toth Financial Advisory Corp bought a new stake in shares of Summit Therapeutics in the 3rd quarter worth approximately $30,000. CX Institutional lifted its holdings in shares of Summit Therapeutics by 244.8% in the 3rd quarter. CX Institutional now owns 2,038 shares of the company's stock worth $34,000 after acquiring an additional 1,447 shares during the last quarter. Eurizon Capital SGR S.p.A. purchased a new stake in shares of Summit Therapeutics in the 3rd quarter valued at $34,000. Finally, Parallel Advisors LLC boosted its stake in shares of Summit Therapeutics by 4,178.0% in the 1st quarter. Parallel Advisors LLC now owns 2,139 shares of the company's stock valued at $41,000 after purchasing an additional 2,089 shares in the last quarter. 4.61% of the stock is owned by institutional investors.

More Summit Therapeutics News

Here are the key news stories impacting Summit Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and raised its earnings estimates across several periods, forecasting narrower losses for FY2026 (a loss of $1.04 per share versus $1.06 previously) and FY2027 (a loss of $0.98 versus $1.05). Its quarterly estimates were also generally revised toward smaller losses. These are forecasts, not reported results. Summit Therapeutics analyst estimate report
• Positive Sentiment: A separate report grouped Summit among healthcare stocks analysts are bullish on, reinforcing the favorable analyst tone. Analysts Are Bullish on These Healthcare Stocks
• Neutral Sentiment: Another article notes SMMT moved above its 200-day moving average, a potentially constructive technical signal, but its headline raises the question of selling and provides no clear investment recommendation. Summit Therapeutics stock breaks above 200-day moving average

Summit Therapeutics Company Profile

Summit Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its lead candidate is ivonescimab, a bispecific antibody designed to target both PD-1 and VEGF, two pathways involved in tumor growth and the immune response. The company is evaluating the treatment in clinical trials for multiple types of cancer.

Summit licensed rights to develop and commercialize ivonescimab from China-based Akeso in 2022. Summit's licensed territory covers markets outside China, including the United States, Canada, Europe and Japan.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.